What are the clinical applications of terlipressin in complications of cirrhosis? Guideline consensus

Cirrhosis, which has a high number of people and a high risk of death, is an

Clinical application of terlipressin in complications of cirrhosis

1.

Guidance Statement 1: Terlipressin is recommended for the treatment of acute esophageal gastric variceal bleeding

Guidance Note 2: In patients with acute gastrointestinal bleeding with cirrhosis, terlipressin

Guidance Statement 3: For patients with acute gastrointestinal bleeding with renal insufficiency in cirrhosis, the use of terlipressin

2.

Guidance Statement 4: Terlipressin is recommended for the treatment

3.
Cirrhosis with ascites

Guidance Statement 5: Terlipressin
may be considered in patients with cirrhosis with severe ascites or refractory ascites if diuretics are ineffective or cannot tolerate diuretic-related adverse effects.

4.
Circulatory dysfunction after a large amount of peritoneal puncture (>5L) after ascites

Guidance Note 6: Terlipressin is recommended for the prevention of circulatory dysfunction following a large (>5L) ascites in patients with cirrhosis and ascites
.

5.
Cirrhosis with bacterial infection

Guidance Note 7: In patients with cirrhosis with bacterial infection, terlipressin may be considered to improve systemic hemodynamic status, microcirculation, and tissue perfusion
.

6.
Hepatic resection

Guidance Note 8: Terlipressin reduces intra- and postoperative portal vein pressure during and after hepatic resection and helps reduce intraoperative blood loss and transfusion needs
.

7.
Liver transplantation

Guidance Note 9: Terlipressin can be used to improve systemic hemodynamic status and renal function
after liver transplantation.

References: Hepatobiliary Disease Group of The Gastroenterology Branch of the Chinese Medical Association, Hepatology Committee of the Chinese Association of Research Hospitals.
Practical guidance on the clinical application of terlipressin in complications of cirrhosis (2021 edition).
Journal of Clinical Hepatobiliary Diseases, 2022,38(8): 1733-1738.

See "Read the original text" for the original text.